Neoadjuvant Therapy Changes the Lymphocyte Composition of Tumor-Draining Lymph Nodes in Cervical Carcinoma

Cancer

Volumn 100, Issue 7, 2004, Pages 1418-1428

  Fattorossi, Andrea ^a   Battaglia, Alessandra ^a   Ferrandina, Gabriella ^a   Coronetta, Ferdinando ^a   Legge, Francesco ^a   Salutari, Vanda ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cervical carcinoma; Immune status; Lymphocyte subsets; T regulatory cells; Tumor draining lymph nodes

Indexed keywords

B7 ANTIGEN; CD134 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; PADGEM PROTEIN; T LYMPHOCYTE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMORADIATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE STATUS; INTERNAL ILIAC ARTERY; LYMPH NODE; NATURAL KILLER CELL; PARAAORTIC LYMPH NODE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; T LYMPHOCYTE SUBPOPULATION; TUMOR DRAINING LYMPH NODE; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPH NODES; LYMPHOCYTES; MIDDLE AGED; NEOADJUVANT THERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 1642293364     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20130     Document Type: Article

References (53)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
2. Armstrong TD, Pulaski BA, Ostrand-Rosenberg S. Tumor antigen presentation: changing the rules. Cancer Immunol Immunother. 1998;46:70-74.
3. Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC. A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol. 2001;22:130-136.
4. Heath WR, Carbone FR. Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol. 1999;11:314-318.
5. Saxon A, Portis J. Lymphoid subpopulation changes in regional lymph nodes in squamous head and neck cancer. Cancer Res. 1977;37:1154-1158.
6. Mandell-Brown M, Johnson JT, Rabin BS, Hamill E, Wagner RL. Neck node immunoreactivity in head and neck carcinoma. Otolaryngol Head Neck Surg. 1986;95:500-506.
7. Mantovani G, Serri FG, Macciò A, et al. Functional and surface phenotype study of lymphocyte subsets in peripheral blood and lymph nodes of patients with breast cancer. Cancer Detect Prev. 1989;13:323-332.
8. Farzad Z, Cochran AJ, McBride WH, Gray JD, Wong V, Morton DL. Lymphocyte subset alterations in nodes regional to human melanoma. Cancer Res. 1990;50:3585-3588.
9. Adachi W, Sugenoya A, Iida F. Immune competent cells of regional lymph nodes in colorectal cancer patients: I. Flow cytometric analysis of lymphocyte subpopulation. J Surg Oncol. 1991;46:110-116.
10. Whitford P, Alam SM, George WD, Campbell AM. Flow cytometric analysis of tumour-draining lymph nodes in breast cancer patients. Eur J Cancer. 1992;28:350-356.
11. + cells is suppressed in regional lymph nodes with cancer involvement in patients with gastrointestinal carcinoma. Cancer. 1996;78:1677-1685.
12. Takenoyama M, Yasumoto K, Harada M, et al. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer. Immunobiology. 1996;195:140-151.
13. Verastegui E, Morales R, Barrera JL, et al. Immunological approach in the evaluation of regional lymph nodes of patients with squamous cell carcinoma of the head and neck. Clin Immunol. 2002;102:37-47.
14. Vetto JT, Lum S, Morris A, et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg. 1997;174:258-265.
15. Ishigami S, Natsugoe S, Hokita S, et al. Intranodal antitumor immunocyte infiltration in node-negative gastric cancers. Clin Cancer Res. 2000;6:2611-2617.
16. + T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. Gynecol Oncol. 2001;81:424-432.
17. Santin AD, Hermonat PL, Ravaggi A, et al. Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papilloma-virus 18 E7-pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. Eur J Gynaecol Oncol. 2000;21:17-23.
18. Santin AD, Bellone S, Palmieri M, et al. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol. 2003;89:271-280.
19. Eifel PJ. Chemoradiation for carcinoma of the cervix: advances and opportunities. Radiat Res. 2000;154:229-236.
20. Rose PG, Eifel PJ. Combined radiation therapy and chemotherapy for carcinoma of the cervix. Cancer J. 2001;7:86-94.
21. Mancuso S, Smaniotto D, Benedetti Panici P, et al. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol. 2000;78:324-328.
22. Jurado M, Martinez-Monge R, Garcia-Foncillas J, et al. Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery ± intraoperative electron beam radiotherapy in locally advanced cervical cancer. Gynecol Oncol. 1999;74:30-37.
23. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
24. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Ress. 1999;59:3128-3133.
25. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
26. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772.
27. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606-612.
28. World Health Organization. WHO handbook for reporting results of cancer treatment. Offset publication no. 48:16-21. Geneva: World Health Organization, 1979.
29. Scambia G, Ferrandina G, Distefano M, et al. Is there a place for a less extensive radical surgery in locally advanced cervical cancer patients? Gynecol Oncol. 2001;83:319-324.
30. Pacifici R, Zuccaro P, Cozzi-Lepre A, Di Carlo S, Bacosi A, Fattorossi A. Quantification of the variation due to lysing technique in immunophenotyping of healthy and HIV-infected individuals. Clin Biochem. 1998;31:165-172.
31. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994;180:631-640.
32. De Rosa SC, Herzenberg LA, Herzenberg LA, Roederer M. 11-Color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nat Med. 2001;7:245-248.
33. Petty JK, He K, Corless CL, Vetto JT, Weinberg AD. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg. 2002;183:512-518.
34. Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 1996;56:4338-4342.
35. Rohn WM, Lee YJ, Benveniste EN. Regulation of class II MHC expression. Crit Rev Immunol. 1996;16:311-330.
36. high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245-1253.
37. Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol. 2002;169:6210-6217.
38. Hamann D, Kostense S, Wolthers KC, et al. Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division. Int Immunol. 1999;11:1027-1033.
39. Baars PA, Ribeiro Do Couto LM, Leusen JH, et al. Cytolytic mechanisms and expression of activation-regulating receptors on effector-type CD8+CD45RA+CD27- human T cells. J Immunol. 2000;165:1910-1917.
40. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295-302.
41. Fattorossi A, Battaglia A, Malinconico P, et al. Constitutive and Inducible Expression of the epithelial antigen MUC1 (CD227) in human T cells. Exp Cell Res. 2002;280:107-118.
42. Baran J, Kowalczyk D, Ozog M, Zembala M. Three-color flow cytometry detection of intracellular cytokines in peripheral blood mononuclear cells: comparative analysis of phorbol myristate acetate-ionomycin and phytohemagglutinin stimulation. Clin Diagn Lab Immunol. 2001;8:303-313.
43. Ronchetti A, Rovere P, Iezzi G, et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol. 1999;163:130-136.
44. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med. 2000;191:423-434.
45. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol. 2000;12:1539-1546.
46. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity. 1998;8:657-665.
47. Baars A, Buter J, Pinedo HM. Making use of the primary tumour. Bioessays. 2003;25:79-86.
48. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253-257.
49. + T cells in autoimmune diabetes. Nat Immunol. 2001;2:1117-1125.
50. Santin AD. Lymph node metastases. The importance of microenvironment. Cancer. 2000;88:175-179.
51. Santin AD, Parham GP. Routine lymph node dissection in the treatment of early stage cancer: are we doing the right thing? Gynecol Oncol. 1998;68:1-3.
52. Keys HM, Bundy BN, Stehamn, FB. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161.
53. Thomas GM. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;40:1198-2000.